1 Systems biology approach to studying p roliferation - dependent prognostic subnetworks in breast cancer Qianqian Song 1 , 2 , Hongyan Wang 1 , Jiguang Bao 2 , Ashok K . Pullikuth 3 , King C . Li 1 , Lance D . Miller 3 and Xiaobo Zhou 1 , 3 , * 1 Division of Radiology , Wake Forest School of Medicine , Winston - Salem , NC 27157 , USA 2 School of Mathematical Sciences , Beijing Normal University , Beijing , 100875 , P R China 3 Department of Cancer Biology , Wake Forest School of Medicine , Winston - Salem , NC , 27157 , USA * Corresponding author Email addresses : Q . S . : wasqqdyx @ gmail . com H . W . : jojowang . business @ gmail . com J . B . : jgbao @ bnu . edu . cn A . K . P . : apulliku @ wakehealth . edu K . C . L . : kingli @ wakehealth . edu L . D . M . : ldmiller @ wakehealth . edu X . Z . : xizhou @ wakehealth . edu 2 Figure S1 . Cross - validated Kaplan - Meier survival curves of P - high tertile in our BR dataset . The figure presented the result of cross - validation on our BR dataset . The red color represented good outcome patients ( low - risk ) , while the green color represented poor outcome patients ( high - risk ) . The significant P - value declared the robustness of our model . 0 2 4 6 8 10 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time ( years ) P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 272 ( Ph ) poor outcome n = 380 P . value = 2 . 62e - 04 poor outcome n = 427 P = 2 . 62e - 04 P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 2 4 6 8 10 good outcome n = 225 Time ( years ) 3 Figure S2 . SPNs in the P - inter group , i . e . P - inter SPNs . There are 8 SPNs discovered in the inter proliferation ( P - inter ) group . Genes are color coded ( i . e . red / green : genes that are overexpressed / underexpressed in patients with shorter DMFS ) . In the color bar , deep green means that log2 ( fold change ) < 0 , ligh green or light red represents that 0 < fold change < 1 ， while deep red means that log2 ( fold change ) > 0 . Details about P - inter SPNs can be found in the Results section . GDI1 RAC1 RAP1B ARFGAP1 RACGAP1 RAB7A MAD2L1 PSMC6 ACTC1 RIT1 RPL23 UBE2D1 CUL1 BTRC FBXW4 EIF3I FBXO7 RPS27A EPS15L1 TRAF6 RAC1 PIR ARFGAP1 MAD2L1 ACTC1 PSMC6 RACGAP1 PLXNA3 MST4 TGM2 RAC1 CASP3 RACGAP1 FADD RAB7A NOL3 STK38L IL2RB SP1 IFT57 HTT HSD17B4 GLUD1 FURIN IMPDH2 STAT5A IGFBP2 IL2RB HOXA7 E2F3 SP1 HTT IMPDH2 GLUD1 IL1B GLUD1 CDK6 SP1 IMPDH2 IFT57 EDNRB MAX HTT FURIN MYCL1 ( 2 ) ( 3 ) IMPDH2 IL2RB MYBPC1 IGFBP2 USF2 SP1 LAMA3 ACTN2 SERPINA1 TYMS ( 1 ) ( 5 ) ( 6 ) ( 4 ) ( 8 ) ( 7 ) Gene expression higher in patients with shorter DMFS higher in patients with longer DMFS 4 Figure S3 . SPNs in the P - low group , i . e . P - low SPNs . There are 6 SPNs discovered in the low proliferation ( P - low ) group . Genes are color coded ( i . e . red / green : genes that are overexpressed / underexpressed in patients with shorter DMFS ) . In the color bar , deep green means that log2 ( fold change ) < 0 , ligh green or light red represents that 0 < fold change < 1 ， while deep red means that log2 ( fold change ) > 0 . Details about P - low SPNs can be found in the Results section . ARPC5 HSP90B1 CTTN RHEB CTNNA1 PCDH17 BRAF RAP2C RAP1B TG CBL RIT1 CHN1 IL4R RAC1 CTTN RAP1B GDI1 SOS2 RAP1B ARPC5 PSMA2 CTTN CTNNA1 PCDH17 AURKA ARHGEF7 PSMD7 CDK4 PRKCH CDKN2A STAT5A MAPKAPK3 RBX1 POLI CDKN1C PEBP1 CUL4A ZNF395 PSMA2 PCDH17 CTTN PSMD7 RAP1B PAK2 CTNNA1 VAV1 CTNNA1 ARPC5 RAP1B APC PSMA2 PCDH17 CTTN PSMA7 ( 2 ) ( 3 ) ( 1 ) ( 5 ) ( 6 ) ( 4 ) Gene expression higher in patients with shorter DMFS higher in patients with longer DMFS 5 Figure S4 . Classification performance of makers identified by different methods in predicting breast cancer metastasis . We calculated the accuracy , precision and recall of correct classification into metastatic - / non - metastatic patient groups based on our identified SPNs . The color of number corresponds to the color of bar , for example , in the P - high test set , the accuracy , precision and recall are 88 . 24 % , 83 . 74 % , 75 . 33 % , respectively . The classification accuracy , precision and recall achieved by different methods ( the Ridge - based Cox model and CRANE method ) were also reported in the figure . 88 . 24 % 84 . 50 % 89 . 28 % 74 . 71 % 77 . 65 % 75 . 83 % 57 . 06 % 63 . 85 % 58 . 82 % 83 . 74 % 80 . 26 % 86 . 69 % 70 . 26 % 75 . 45 % 71 . 38 % 53 . 74 % 67 . 22 % 62 . 22 % 75 . 33 % 77 . 49 % 89 . 17 % 78 . 82 % 72 . 78 % 75 . 23 % 65 . 33 % 61 . 43 % 51 . 43 % 0 . 00 % 10 . 00 % 20 . 00 % 30 . 00 % 40 . 00 % 50 . 00 % 60 . 00 % 70 . 00 % 80 . 00 % 90 . 00 % 100 . 00 % S P N _ H i g h S P N _ I n t er S P N _ L o w C R A N E _ H i g h C R A N E _ I n t er C R A N E _ L o w R i d g e _ H i g h R i d g e _ I n t er R i d g e _ L o w accuracy precision recall 6 Figure S5 . Enrichment analysis of P - inter SPNs in BP sets and KEGG pathway sets . Subfigure A . showed the enrichment of P - inter SPNs in biological process ( BP ) sets , while subfigure B . was the enrichment of P - inter SPNs in KEGG pathway sets . Enriched biological process or pathway ( i . e . enrichment ) was indicated by yellow , whereas non - enrichment was indicated by blue . X2 X5 X6 KEGG _ VIRAL _ MYOCARDITIS KEGG _ COLORECTAL _ CANCER KEGG _ PATHWAYS _ IN _ CANCER KEGG _ EPITHELIAL _ CELL _ SIGNALING _ IN _ HELICOBACTER _ PYLORI _ INFECTION KEGG _ HUNTINGTONS _ DISEASE KEGG _ AMYOTROPHIC _ LATERAL _ SCLEROSIS _ ALS KEGG _ APOPTOSIS KEGG _ UBIQUITIN _ MEDIATED _ PROTEOLYSIS SPN 2 5 6 Ubiquitin _ Mediated _ Proteolysis Apoptosis Amyotrophic _ Lateral _ Sclerosis _ ALS Huntingtons _ Disease Epithelial _ Cell _ Signaling _ In _ Infection Pathways _ In _ Cancer Colorectal _ Cancer Viral _ Myocraditis B . KEGG pathways enrichment in P - inter SPNs 1 2 14 13 12 11 10 9 8 7 6 5 4 3 2 1 SPN 2 4 Biopolymer _ Catabolic _ Process Protein _ Polyubiquitination Cellular _ Protein _ Catabolic _ Process Cellular _ Catabolic _ Process Protein _ Modification _ by _ Small _ Protein _ Conjugation Protein _ Ubiquitination Protein _ Catabolic _ Process Proteolysis Cellular _ Protein _ Metabolic _ Process Macromolecule _ Catabolic _ Process Cellular _ Macromolecule _ Catabolic _ Process Cellular _ Macromolecule _ Metabolic _ Process Catabolic _ Process Ubiquitin _ Cycle A . Biological Processes enrichment in P - inter SPNs 7 Figure S6 . Enrichment analysis of P - low SPNs in BP sets and KEGG pathway sets . Subfigure A . showed the enrichment of P - low SPNs in biological process ( BP ) sets , while subfigure B . was the enrichment of P - low SPNs in KEGG pathway sets . Enriched biological process or pathway ( i . e . enrichment ) was indicated by yellow , whereas non - enrichment was indicated by blue . B . KEGG pathways enrichment in P - low SPNs X1 X5 KEGG _ NON _ SMALL _ CELL _ LUNG _ CANCER KEGG _ CHRONIC _ MYELOID _ LEUKEMIA KEGG _ BLADDER _ CANCER KEGG _ MELANOMA KEGG _ GLIOMA KEGG _ ENDOMETRIAL _ CANCER KEGG _ PANCREATIC _ CANCER KEGG _ RENAL _ CELL _ CARCINOMA KEGG _ PATHWAYS _ IN _ CANCER KEGG _ PATHOGENIC _ ESCHERICHIA _ COLI _ INFECTION KEGG _ INSULIN _ SIGNALING _ PATHWAY KEGG _ NEUROTROPHIN _ SIGNALING _ PATHWAY KEGG _ LONG _ TERM _ POTENTIATION KEGG _ LEUKOCYTE _ TRANSENDOTHELIAL _ MIGRATION KEGG _ FC _ EPSILON _ RI _ SIGNALING _ PATHWAY KEGG _ B _ CELL _ RECEPTOR _ SIGNALING _ PATHWAY KEGG _ T _ CELL _ RECEPTOR _ SIGNALING _ PATHWAY KEGG _ NATURAL _ KILLER _ CELL _ MEDIATED _ CYTOTOXICITY KEGG _ JAK _ STAT _ SIGNALING _ PATHWAY KEGG _ FOCAL _ ADHESION KEGG _ MTOR _ SIGNALING _ PATHWAY KEGG _ P53 _ SIGNALING _ PATHWAY KEGG _ CELL _ CYCLE KEGG _ CHEMOKINE _ SIGNALING _ PATHWAY KEGG _ ERBB _ SIGNALING _ PATHWAY KEGG _ MAPK _ SIGNALING _ PATHWAY KEGG _ NUCLEOTIDE _ EXCISION _ REPAIR KEGG _ PROTEASOME SPN 1 2 4 5 6 KEGG _ Proteasome Nucleotide _ Excision _ Repair MAPK _ Signaling _ Pathway ERBB _ Signaling _ Pathway Chemokine _ Signaling _ Pathway Cell _ Cycle P53 _ Signaling _ Pathway MTOR _ Signaling _ Pathway Focal _ Adhesion JAK _ STAT _ Signaling _ Pathway Natural _ Killer _ Cell _ Mediated _ Cytotoxicity T _ Cell _ Receptor _ Signaling _ Pathway B _ Cell _ Receptor _ Signaling _ Pathway FC _ Epsilon _ RI _ Signaling _ Pathway Leukocyte _ Transendothelial _ Migration Long _ Term _ Potentiation Neurotrophin _ Signaling _ Pathway Insulin _ Signaling _ Pathway Pathogenic _ Escherichia _ Coli _ Infection Pathways _ In _ Cancer Renal _ Cell _ Carcinoma Pancreatic _ Cancer Endometrial _ Cancer Glioma Melanoma Bladder _ Cancer Chronic _ Myeloid _ Leukemia Non _ Small _ Cell _ Lung _ Cancer X2 X5 G1 _ S _ TRANSITION _ OF _ MITOTIC _ CELL _ CYCLE REGULATION _ OF _ CELL _ PROLIFERATION REGULATION _ OF _ CELL _ CYCLE INTERPHASE _ OF _ MITOTIC _ CELL _ CYCLE CELL _ CYCLE _ GO _ 0007049 CELL _ CYCLE _ ARREST _ GO _ 0007050 REGULATION _ OF _ ENDOCYTOSIS CELL _ PROLIFERATION _ GO _ 0008283 REGULATION _ OF _ CYCLIN _ DEPENDENT _ PROTEIN _ KINASE _ ACTIVITY NEGATIVE _ REGULATION _ OF _ CELL _ PROLIFERATION CELL _ CYCLE _ PHASE MITOTIC _ CELL _ CYCLE CELL _ CYCLE _ PROCESS INTERPHASE NEGATIVE _ REGULATION _ OF _ CELL _ CYCLE SPN 2 5 Negative _ Regulation _ of _ Cell _ Cycle Interphase Cell _ Cycle _ Process Mitotic _ Cell _ Cycle Cell _ Cycle _ Phase Negative _ Regulation _ of _ Cell _ Proliferation Regulaion _ of _ Cyclin _ Dependent _ Protein _ Kinase _ Activity Cell _ Proliferation Regulation _ of _ Endocytosis Cell _ Cycle _ Arrest Cell _ Cycle Interphase _ of _ Mitotic _ Cell _ Cycle Regulation _ of _ Cell _ Cycle Regulation _ of _ Cell _ Proliferation G1 _ S _ Transition _ of _ Mitotic _ Cell _ Cycle A . Biological Processes enrichment in P - low SPNs 8 Figure S7 . Survival analysis of the dataset used in Wang et al . A . shows the survival curves ( with log - rank P - value ) of P - high subset in Wang et al . ’s dataset . B . shows the survival curves of P - inter subset in Wang et al . ’s dataset . C . shows the survival curves of P - low subset in Wang et al . ’s dataset . 0 2 4 6 8 12 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 77 ( Ph ) poor outcome n = 19 p = 0 . 0058 good outcome n = 77 poor outcome n = 19 P = 0 . 0058 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 2 4 6 8 10 12 14 0 2 4 6 8 10 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 28 ( Ph ) poor outcome n = 68 p = 0 . 000543 good outcome n = 28 poor outcome n = 68 P = 0 . 000543 Time ( years ) P r o b a b ili t y o f D M F S 0 2 4 6 8 10 12 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 2 4 6 8 10 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 45 ( Ph ) poor outcome n = 50 p = 0 . 00714 good outcome n = 45 poor outcome n = 50 P = 0 . 00714 Time ( years ) P r o b a b ili t y o f D M F S 0 2 4 6 8 10 12 0 0 . 2 0 . 4 0 . 6 0 . 8 1 A . P - high subset B . P - inter subset C . P - low subset 9 Figure S8 . Survival curves of two proliferation groups ( P - high group , P - low group ) in test set . A . shows the survival analysis of P - high group in test set . B . shows the survival analysis of P - low group in test set . 0 1 2 3 4 5 6 7 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 52 ( Ph ) poor outcome n = 76 p = 0 . 0168 good outcome n = 52 poor outcome n = 76 P = 0 . 0168 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 A . survival curves in P - high test set 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 30 ( Ph ) poor outcome n = 98 p = 0 . 0258 good outcome n = 30 poor outcome n = 98 P = 0 . 0258 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 B . survival curves in P - low test set 0 1 2 3 4 5 6 7 10 Figure S9 . Survival curves of four proliferation groups ( P - high , P - intermediate I , P - intermediate II , P - low group ) in test set . 0 1 2 3 4 5 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 13 ( Ph ) poor outcome n = 52 p = 0 . 0709 good outcome n = 13 poor outcome n = 52 P = 0 . 0409 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 A . survival curves in P - high test set 0 1 2 3 4 5 0 1 2 3 4 5 6 7 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 20 ( Ph ) poor outcome n = 45 p = 0 . 0592 good outcome n = 20 poor outcome n = 45 P = 0 . 0592 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 B . survival curves in P - intermediate I test set 0 1 2 3 4 5 6 7 0 1 2 3 4 5 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 54 ( Ph ) poor outcome n = 11 p = 0 . 0785 good outcome n = 54 poor outcome n = 11 P = 0 . 0785 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 C . survival curves in P - intermediate II test set 0 1 2 3 4 5 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 2 . 5 3 . 0 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 Time P r obab ili t y o f D M F S ( Ph ) good outcome n = 16 ( Ph ) poor outcome n = 48 p = 0 . 226 good outcome n = 16 poor outcome n = 48 P = 0 . 226 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 D . survival curves in P - low test set 0 0 . 5 1 1 . 5 2 2 . 5 3 11 Figure S10 . Survival analysis of three proliferation tertiles with weights in SPNs . A . shows the survival curves of P - high test set based on the weighted P - high SPNs . B . shows the survival curves and log - rank P - value of P - inter test set based on the weighted P - inter SPNs . C . shows the survival curves of P - low test set based on the weighted P - low SPNs . 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 34 ( Ph ) poor outcome n = 51 p = 0 . 145 good outcome n = 34 poor outcome n = 51 P = 0 . 145 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 4 5 6 7 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 2 ( Ph ) poor outcome n = 83 p = 0 . 508 good outcome n = 2 poor outcome n = 83 P = 0 . 508 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 4 5 6 7 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 59 ( Ph ) poor outcome n = 26 p = 0 . 00528 good outcome n = 59 poor outcome n = 26 P = 0 . 00528 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 4 5 6 7 0 0 . 2 0 . 4 0 . 6 0 . 8 1 A . P - high test set B . P - inter test set C . P - low test set 12 Figure S11 . Test in different proliferation tertiles by SPNs . A . shows the survival curves of P - inter group based on P - high SPNs . B . shows the survival curves of P - low group based on P - high SPNs . C . shows the survival curves of P - high group based on P - inter SPNs . D . shows the survival curves of P - low group based on 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 42 ( Ph ) poor outcome n = 43 p = 0 . 192 good outcome n = 42 poor outcome n = 43 P = 0 . 192 Time ( years ) P r o b a b ili t y o f D M F S 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 4 5 6 7 A . P - high SPNs test in P - inter tertile 0 1 2 3 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 42 ( Ph ) poor outcome n = 43 p = 0 . 393 good outcome n = 42 poor outcome n = 43 P = 0 . 393 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 0 0 . 2 0 . 4 0 . 6 0 . 8 1 B . P - high SPNs test in P - low tertile 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 32 ( Ph ) poor outcome n = 53 p = 0 . 453 good outcome n = 32 poor outcome n = 53 P = 0 . 453 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 4 5 6 7 C . P - inter SPNs test in P - high tertile 0 1 2 3 4 5 6 7 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 48 ( Ph ) poor outcome n = 37 p = 0 . 842 good outcome n = 48 poor outcome n = 37 P = 0 . 842 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 4 5 6 7 D . P - inter SPNs test in P - low tertile 0 1 2 3 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 49 ( Ph ) poor outcome n = 36 p = 0 . 223 ( Ph ) good outcome n = 49 ( Ph ) poor outcome n = 36 good outcome n = 49 poor outcome n = 36 P = 0 . 223 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 E . P - low SPNs test in P - high tertile 0 1 2 3 0 . 0 0 . 4 0 . 8 Time P r ob a b ili t y o f D M F S ( Ph ) good outcome n = 52 ( Ph ) poor outcome n = 33 p = 0 . 866 good outcome n = 52 poor outcome n = 33 P = 0 . 866 Time ( years ) P r o b a b ili t y o f D M F S 0 1 2 3 0 0 . 2 0 . 4 0 . 6 0 . 8 1 0 1 2 3 F . P - low SPNs test in P - inter tertile 13 P - inter SPNs . E . shows the survival curves of P - high group based on P - low SPNs . F . shows the survival curves of P - inter group based on P - low SPNs . Supplementary Table S1 . Adjusted P - values of P - high , P - inter and P - low SPNs . Supplementary Table S2 . Clinical and pathological characteristics of test set . adjust P - value 3 . 33E $ 16 P - high P - inter P - low 1 . 11E $ 15 6 . 02E $ 15 1 . 11E $ 16 2 . 45E $ 16 1 . 67E $ 15 1 . 33E $ 15 1 . 23E $ 15 1 . 22E $ 15 9 . 99E $ 16 1 . 22E $ 16 1 . 11E $ 16 2 . 22E $ 16 5 . 11E $ 16 1 . 45E $ 16 of SPNs # 3 # 2 # 1 2 . 22E $ 16 3 . 77E $ 15 1 . 39E $ 15 1 . 12E $ 16 # 8 # 5 # 4 1 . 11E $ 16 1 . 67E $ 16 5 . 55E $ 16 # 6 # 7 test set * ( n = 255 ) Age , years < = 40 46 ( 18 . 43 % ) 41 - 55 128 ( 50 . 2 % ) 56 - 70 74 ( 29 % ) > 70 7 ( 2 . 37 % ) T stage T0 2 ( 0 . 78 % ) T1 19 ( 7 . 45 % ) T2 133 ( 52 . 16 % ) T3 / 4 101 ( 39 . 61 % ) Grade Poor 121 ( 47 . 45 % ) Moderate 98 ( 38 . 43 % ) Good 13 ( 5 . 1 % ) Unkown 23 ( 9 . 02 % ) ER status Positive 148 ( 58 . 04 % ) Negative 107 ( 41 . 96 % ) Subtype Normal 24 ( 9 . 41 % ) LumA 81 ( 31 . 77 % ) LumB 34 ( 13 . 3 % ) Her2 19 ( 7 . 45 % ) Basal 97 ( 38 . 04 % ) Metastasis within 5 years Yes 59 ( 23 . 14 % ) No 196 ( 76 . 86 % ) * samples in test set are extracted from GSE25055 Characteristics 14 Supplementary Table S3 . Affymetrix probe sets and gene names that comprise the proliferation metagene . Proliferation Metagene Probe Set ID Gene Symbol Gene Name 201291 _ s _ at TOP2A Topoisomerase ( DNA ) II alpha 170kDa 201292 _ at TOP2A Topoisomerase ( DNA ) II alpha 170kDa 201890 _ at RRM2 Ribonucleotide reductase M2 202095 _ s _ at BIRC5 Baculoviral IAP repeat - containing 5 202503 _ s _ at KIAA0101 KIAA0101 202580 _ x _ at FOXM1 Forkhead box M1 202589 _ at TYMS Thymidylate synthetase 202705 _ at CCNB2 Cyclin B2 202870 _ s _ at CDC20 Cell division cycle 20 homolog ( S . cerevisiae ) 202954 _ at UBE2C Ubiquitin - conjugating enzyme E2C 203213 _ at CDK1 Cyclin - dependent kinase 1 203214 _ x _ at CDK1 Cyclin - dependent kinase 1 203362 _ s _ at MAD2L1 MAD2 mitotic arrest deficient - like 1 ( yeast ) 203554 _ x _ at PTTG1 Pituitary tumor - transforming 1 203755 _ at BUB1B Budding uninhibited by benzimidazoles 1 homolog beta ( yeast ) 203764 _ at DLGAP5 Discs , large ( Drosophila ) homolog - associated protein 5 204026 _ s _ at ZWINT ZW10 interactor 204033 _ at TRIP13 Thyroid hormone receptor interactor 13 204092 _ s _ at AURKA Aurora kinase A 208079 _ s _ at AURKA Aurora kinase A 204162 _ at NDC80 NDC80 homolog , kinetochore complex component ( S . cerevisiae ) 204170 _ s _ at CKS2 CDC28 protein kinase regulatory subunit 2 204444 _ at KIF11 Kinesin family member 11 204641 _ at NEK2 NIMA ( never in mitosis gene a ) - related kinase 2 204822 _ at TTK TTK protein kinase 204825 _ at MELK Maternal embryonic leucine zipper kinase 204962 _ s _ at CENPA Centromere protein A 205034 _ at CCNE2 cyclin E2 205046 _ at CENPE Centromere protein E , 312kDa 206102 _ at GINS1 GINS complex subunit 1 ( Psf1 homolog ) 206364 _ at KIF14 Kinesin family member 14 207828 _ s _ at CENPF Centromere protein F , 350 / 400kDa ( mitosin ) 209172 _ s _ at CENPF Centromere protein F , 350 / 400kDa ( mitosin ) 209408 _ at KIF2C Kinesin family member 2C 209642 _ at BUB1 Budding uninhibited by benzimidazoles 1 homolog ( yeast ) 209714 _ s _ at CDKN3 Cyclin - dependent kinase inhibitor 3 209773 _ s _ at RRM2 Ribonucleotide reductase M2 210052 _ s _ at TPX2 TPX2 , microtubule - associated , homolog ( Xenopus laevis ) 210559 _ s _ at CDK1 Cyclin - dependent kinase 1 212022 _ s _ at MKI67 Antigen identified by monoclonal antibody Ki - 67 212949 _ at NCAPH Non - SMC condensin I complex , subunit H 213226 _ at CCNA2 Cyclin A2 214710 _ s _ at CCNB1 Cyclin B1 218009 _ s _ at PRC1 Protein regulator of cytokinesis 1 218039 _ at NUSAP1 Nucleolar and spindle associated protein 1 218355 _ at KIF4A Kinesin family member 4A 218542 _ at CEP55 Centrosomal protein 55kDa 218585 _ s _ at DTL Denticleless homolog ( Drosophila ) 218662 _ s _ at NCAPG Non - SMC condensin I complex , subunit G 218663 _ at NCAPG Non - SMC condensin I complex , subunit G 218726 _ at HJURP Holliday junction recognition protein 218755 _ at KIF20A Kinesin family member 20A 218883 _ s _ at MLF1IP MLF1 interacting protein 219148 _ at PBK PDZ binding kinase 219306 _ at KIF15 Kinesin family member 15 219918 _ s _ at ASPM asp ( abnormal spindle ) homolog , microcephaly associated ( Drosophila ) 220651 _ s _ at MCM10 Minichromosome maintenance complex component 10 221436 _ s _ at CDCA3 Cell division cycle associated 3 221520 _ s _ at CDCA8 Cell division cycle associated 8 222039 _ at KIF18B Kinesin family member 18B 222077 _ s _ at RACGAP1 Rac GTPase activating protein 1 204562 _ at IRF4 Interferon regulatory factor 4 15 Supplementary Table S4 . Overlap of genes among the SPNs , Chuang et . al , CRANE and the Cox - based Ridge regression method . SPN CRANE Ridge Gene Symbol 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 11 1 GNG11 TUBB6 COBRA1 SMAD2 CALM1 IGFBP7 DCTN2 HSPA1A TBCA MNAT1 ASPM CBX3 POLR2H HSP90AA1 TBCE TUBB2C STK3 CALD1 RDBP CDK7 CCR9 SFN NPM1 CTTN IGF1R TUBA1A TAX1BP1 LAMA3 XPO1 VEGFA STUB1 KTN1 THBS3 GNG10 UBE2D2 SPP1 DNAJA3 RAP1GAP RNF41 16 ITGA3 GLI3 CD151 FBXW11 CHST2 NUDT9 PRKCZ FEZ2 VAV1 IL6ST KRT10 NLRP1 MCM7 YWHAQ MAGOH CR1 PCGF2 SMARCA5 GRB14 AKAP8 ASF1A RAD21 TRAF6 NFKB1 C3 PDGFRA CHEK2 SKAP1 CREB3L2 M6PR SP140L TAF9 PSMB10 TXNIP TAPBPL ARHGEF18 LPIN1 DTNB NDUFS6 BTF3 IP6K1 CD72 PTGER4 MSN 17 BCL11A CCDC88A TNNT1 CD37 QKI TCEAL4 RARRES1